Print this pageParticipating Agencies Web Sites
Learn more about how the participating agencies use the WA PDL, dispensing guidelines specific to each agency, and contact information to the participating programs:
The only drug classes subject to TIP are those listed below that have been reviewed by the P&T Committee and selected for the PDL by the three participating agencies. The P&T Committees Schedule of Drug Reviews is available online.
Therapeutic Interchange Program Announcements
TIP announcements or updates to a class of drugs covered under the Washington PDL are listed below.
For archived or previous announcements on a drug class listed, please contact Regina Chacon at (206) 521-2027.
082007 ACE, Antiplatelet,CCB, Hep C, NSH, SMR, TIM, Triptans, 5HT3 (57 KB)- 111907_PPI_5HT3 (48.5 KB)
- ACE Inhibitor (ACE-I) (444.8 KB)
- Alzheimer disease, drugs to treat (48.3 KB)
- Antiemetic - 5HT3 (446.5 KB)
- Antiplatelet (445 KB)
- Attention Deficit /Hyperactivity Disorder (ADHD) (45.8 KB)
- Atypical Anti-Psychotic (AAP) (53 KB)
- Beta Agonists (49.5 KB)
- Beta Blocker (445.4 KB)
- Calcium Channel Blocker (CCB) (52.2 KB)
- Estrogen (48 KB)
- Inhaled Corticosteroid (ICS) (49.1 KB)
- Long Acting Opioid (LAO) (47.8 KB)
- Macrolide (47.9 KB)
- Nasal Corticosteroid (47.6 KB)
- Newer Antihistamine (formerly Non-Sedating Antihistamine - NSA) (47.8 KB)
- Nonsteroidal Anti-inflammatory Drug & COX II Inhibitor (NSAID / COX-II) (48.9 KB)
- Oral Hypoglycemic (51.4 KB)
- Over Active Bladder, drugs to treat (OAB) (445.4 KB)
- Proton Pump Inhibitor (PPI) (47.8 KB)
- Second Generation Antidepressant (54.7 KB)
- Antidepressant Refill Flowchart (30.6 KB)
- Skeletal Muscle Relaxer (SMR) (51.2 KB)
- Statin (48.5 KB)
- Targeted Immune Modulator (TIM) (445.5 KB)
- Thiazolidinedione Antidiabetic (TZD) (52 KB)
- Triptan (47.5 KB)
Supplemental Rebates
(DSHS - HRSA only)
Sealed bids should be mailed to:
Robin Arnold-Williams, Secretary
Department of Social and Health Services
P.O. Box 45010
14th & Jefferson Street
Olympia, WA 98504-5010
Faxes or electronic submissions will not be accepted. No bids will be entertained until the drug class is evaluated per the P&T Committee schedule. If you have questions about specific drugs that are included in these drug class reviews, please contact Siri Childs, Pharm D. with DSHS-HRSA at 360-725-1564.
